最新ニュース Novo Nordisk (NYSE:NVO) 株価情報

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Equities

News

Markets

LCID

RIVN

TSLA

米国株は反発し、結果はまちまちにダウ平均は0.8％近く下落し、39,112.16ドルでした。一方、S&amp;P 500は0.4％以上上昇し、5,469.30ドルでレギュラーセッションを終えました。ナスダック指数はほぼ1.3％上昇し、17,717.65ドルで取引を終了しました。これらは、小売トレーダーや投資家の関心を集めたトップ銘柄です。

マイクロンが相場を牽引か　本日注目すべき株式

Health Care

Global

「ノーボ・ノルディスク (NYSE:NVO) は、同社の減量薬の需要増加に対応するため、米国での製造拠点の拡大に41億ドルを投資する予定だ。出来事：ノルウェーの製薬会社は、同社が発表したリリースの中で、北カロライナ州のローリー近くに新しい140万平方フィートの製造工場を建設する予定で、これにより同社製造拠点の規模が倍増するという。 この追加生産能力は、2027年から2029年の間に運用される予定だ。

ノーボ・ノルディスク　米製造拠点に41億円を投資

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

According to multiple media reports on Thursday, Pfizer&nbsp;Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez.
In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years" rel="noreferrer noopener">uniQure/ CSL Behring&#8217;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years</a>
In a statement to&nbsp;Nikkei Asia, Pfizer <a target="_blank" href="https://asia.nikkei.com/Business/Pharmaceuticals/Pfizer-halts-work-on-hemophilia-gene-therapy" rel="noreferrer noopener">said</a> the decision was due to "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.&#8221;
The U.S. drugmaker said it would focus on different treatment for the disorder, citing low interest.
In December 2024, Pfizer walked away&nbsp;from its hemophilia A co-development pact with Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) giroctocogene fitelparvovec, an investigational gene <a target="_blank" href="https://www.benzinga.com/24/12/42740738/sangamo-therapeutics-stock-plunges-as-pfizer-terminates-hemophilia-gene-therapy-pact" rel="noreferrer noopener">therapy product candidate</a>.
According to a Reuters report, Pfizer will continue to invest resources in Hympavzi (marstacimab-hncq), which is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A or hemophilia B.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">auto-injector pen</a>.
Earlier this month, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">with and without inhibitors</a>.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta&nbsp;(voxelotor) for sickle cell disease (SCD) in all markets&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41035514/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worl" rel="noreferrer noopener">where it is approved</a>.
Pfizer's decision is based on the totality of clinical data indicating that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048780/pfizer-voluntarily-withdraws-sickle-cell-disease-treatment-oxbryta-from-global-market-due-to-pain" rel="noreferrer noopener">cell patient population</a>.
Price Action: PFE stock is up 0.87% at $26.13 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43885302/apple-expands-apple-tv-to-android-eyes-subscription-growth-and-ecosystem-expansion-analyst-says" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>

Biotech

Large Cap

General

SGMO

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

WIIM

Novo Nordisk shares are trading higher after the FDA announced that the injection shortage for the company's Ozemic and Wegovy injections is resolved.

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

RHHBY

TERN

VANI

VKTX

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Hims & Hers Health shares are trading lower after the company announced it acquired a U.S.-based peptide facility. Additionally, it was reported that the FDA said the semaglutide injection shortage is resolves as of Feb. 21.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $136,075 and 10, calls, for a total amount of $989,743.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $125.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $70.0 to $125.0 in the last 30 days. 
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739992546_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.3</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$110.00</td>
<td>$606.0K</td>
<td>1.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.0</td>
<td>$17.8</td>
<td>$18.0</td>
<td>$95.00</td>
<td>$106.2K</td>
<td>601</td>
<td>60</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.65</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$85.00</td>
<td>$73.2K</td>
<td>2.1K</td>
<td>95</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.0</td>
<td>$17.8</td>
<td>$17.8</td>
<td>$75.00</td>
<td>$53.4K</td>
<td>199</td>
<td>2</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$14.95</td>
<td>$14.7</td>
<td>$14.85</td>
<td>$70.00</td>
<td>$46.0K</td>
<td>44</td>
<td>31</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,760,951, the NVO's price is up by 1.01%, now at $83.16. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 2.2% on an annualized basis producing an average annual return of 13.35%. Currently, Novo Nordisk has a market capitalization of $367.86 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $3,489.99 today based on a price of $82.87 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739979008_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) filed an urgent request for a worldwide freezing order against KBP Biosciences Pte. Ltd. and Dr. Huang Zhenhua, KBP's founder, Executive Chairman and a 40% shareholder.
The case revolves around Novo Nordisk's claim that KBP misled it into buying the rights to Ocedurenone, a drug for hypertension and kidney disease.
Novo argues that KBP failed to disclose crucial data suggesting the drug was ineffective.
In October 2023, Novo Nordisk <a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166329" rel="noreferrer noopener">agreed</a> to acquire ocedurenone for up to $1.3 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data</a>
At that time, the company said Ocedurenone was being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease.
In June 2024, Novo Nordisk <a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=168529" rel="noreferrer noopener">announced</a> that the CLARION-CKD phase 3 trial failed to meet its primary endpoint. The Danish drug giant recognized an impairment loss of around 5.7 billion Danish kroner related to the intangible asset ocedurenone.
Tucked in its third-quarter earnings release, Novo Nordisk <a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/11f24e9a-5374-4abf-afc1-a31bc257a98a" rel="noreferrer noopener">said</a> that following the stop of the ocedurenone CLARION-CKD phase 3 trial, based on the interim analysis in June, Novo Nordisk has analyzed detailed trial data and decided to terminate further development of ocedurenone.
Novo Nordisk is <a target="_blank" href="https://www.elitigation.sg/gd/sic/2025_SGHCI_3" rel="noreferrer noopener">seeking</a> this order as part of a planned arbitration in New York, where it intends to claim $830 million in damages, with $100 million already held in escrow.
The judge says, "KBP knowingly failed to disclose material information, including interim analyses of Phase 2 clinical trial results showing Ocedurenone's inefficacy, and information concerning quality and compliance issues at a single test site that produced anomalous positive results. Likewise, Dr Huang arguably knew and participated in these misrepresentations."
Price Action: NVO stock is up 0.60% at $82.83&nbsp;during the premarket session on last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/02/43810612/wrangler-lee-parent-kontoor-brands-snaps-up-helly-hansen-for-900m-details" target="_blank" rel="noreferrer noopener">Wrangler &amp; Lee Parent Kontoor Brands Snaps Up Helly Hansen For $900M: Details</a></li>
</ul>
Photo via Shutterstock

Legal

Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages

Novo Nordisk shares are trading higher. The stock may be moving after Sanofi announced FDA approval for Merilog, its first rapid-acting insular product for diabetes, which is biosimilar to Novo Nordisk's insulin products.

On Friday, the FDA approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Merilog as a biosimilar to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a>
As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes" rel="noreferrer noopener">approval </a>is for a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.
Merilog is the third insulin biosimilar product the FDA has approved, joining the two long-acting insulin biosimilar products the agency approved in 2021.
A biosimilar is a &#8220;biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product).&#8221; The FDA has approved 65 biosimilar products to date.
Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs, or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient&#8217;s needs.
Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions, and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain, and swelling of hands and feet.
In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to&nbsp;lower the price of its best-selling insulin product, Lantus <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">(insulin glargine), by 78%</a>.
Sanofi said it would cap a&nbsp;Lantus patient&#8217;s monthly out-of-pocket cost at $35 for all patients with commercial insurance.&nbsp;
Also, in 2023, Sanofi acquired&nbsp;Provention Bio for $25.00 per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31318877/provention-bios-2-9b-acquisition-a-strategic-fit-for-sanofi" rel="noreferrer noopener">approximately $2.9 billion</a>.
The transaction adds a type 1 diabetes therapy to Sanofi&#8217;s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.&nbsp;
In November, Doctors Without Borders/Médecins Sans Frontières highlighted that&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk, and Sanofi, which dominate the global insulin market, have the power to set high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price" rel="noreferrer noopener">prices that restrict access</a>.
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
Price Action: SNY stock is down 0.59% at $54.18 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Image by HJBC via Shutterstock

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

U.S. FDA Approves Sanofi-Aventis U.S' Merilog & Merilog Solostar, Biosimilars To Novo Nordisk's Novolog

<a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957425001475/xslForm13F_X02/infotable.xml">https://www.sec.gov/Archives/edgar/data/1167483/000091957425001475/xslForm13F_X02/infotable.xml</a>

AMAT

CPNG

RDDT

SPOT

UBER

Tiger Global Management's Latest 13F Filing Shows Increased Positions In Eli Lilly By 1.31M Shares, Reddit By 2.03M Shares, Coupang By 8.12M Shares, Sherwin-Williams By 1.00M Shares, Spotify By 1.26M Shares; Decreased Holdings In UnitedHealth By 438.8K Shares, Nu Holdings By 8.88M Shares, Uber Technologies By 2.60M Shares, Applied Materials By 895.2K Shares, Novo Nordisk By 1.27M Shares

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 33%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $1,137,714, and 8 are calls, for a total amount of $752,452.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $145.0 for Novo Nordisk over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $50.0 to $145.0 in the last 30 days. 
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739552433_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.3</td>
<td>$6.0</td>
<td>$6.3</td>
<td>$85.00</td>
<td>$362.9K</td>
<td align="right">12</td>
<td align="right">641</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$67.4</td>
<td>$66.15</td>
<td>$66.15</td>
<td>$145.00</td>
<td>$330.7K</td>
<td align="right">4</td>
<td align="right">10</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$70.00</td>
<td>$210.0K</td>
<td align="right">0</td>
<td align="right">501</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.3</td>
<td>$85.00</td>
<td>$195.3K</td>
<td align="right">12</td>
<td align="right">951</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$13.05</td>
<td>$12.0</td>
<td>$12.15</td>
<td>$91.00</td>
<td>$66.8K</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,949,255, the price of NVO is down by -0.2%, reaching $78.67.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

A Closer Look at Novo Nordisk's Options Market Dynamics

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) short percent of float has risen 65.38% since its last report. The company recently reported that it has 13.57 million shares sold short, which is 0.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novo Nordisk Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739538919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novo Nordisk has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novo Nordisk's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novo Nordisk's peer group average for short interest as a percentage of float is 4.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Novo Nordisk?

On Wednesday, Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported a fourth-quarter EPS loss of 64 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 1.07 euros</a>.
Total revenue for the fourth quarter of 2024 was 173.9 million euros, beating the consensus of 111.178 million euros compared to 137.7 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674382/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">euros reported a year ago</a>.
The increase was primarily due to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) $100 million upfront fee and the EU launch of Yorvipath.
TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 million euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug" rel="noreferrer noopener">Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug</a>
TransCon PTH (palopegteriparatide, marketed as Yorvipath) revenue for the fourth quarter of 2024 totaled €13.6 million.
The company reported a strong start to the U.S. Yorvipath launch, with 908 prescriptions as of February 7, 2025, and 539 unique prescribing health care providers.
As of December 31, 2024, cash and cash equivalents totaled 559.5 million euros. Including the $100 million upfront payment, cash at the end of 2024 would have totaled 655 million euros.
Concurrently, Ascendis Pharma's board authorized the repurchase of up <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674574/ascendis-pharma-as-announces-share-repurchase-program-net-settlement-of-certain-rsus" rel="noreferrer noopener">to $18.25 million shares</a>.
Goldman Sachs analyst writes that Yorvipath has only been available in the U.S. for a few months, but early prescription trends have been strong and widespread. However, insurance coverage and reimbursement challenges may slow revenue growth in the short term.
Looking ahead, analyst Paul Choi writes investors will likely focus on the company's progress toward achieving breakeven cash flow and key milestones, including:
<ul>
<li>The pace of Yorvipath's rollout in the U.S. and EU</li>
<li>Data from the COACH study on achondroplasia, expected in Q2 2025</li>
<li>Regulatory discussions on Transcon CNP</li>
<li>Competitive updates from BioMarin Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) in achondroplasia and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) in hypoparathyroidism.</li>
</ul>
With Yorvipath showing potential for a strong launch in 2025, Goldman Sachs maintains the Buy rating and raises the price target <a target="_blank" href="https://www.benzinga.com/quote/CVS/analyst-ratings" rel="noreferrer noopener">to $225 from $200</a>.
Price Action: ASND stock is up 15.8% at $146.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">Zoetis Drops As 2025 Guidance Falls Short Of Estimates</a></li>
</ul>

Analyst Color

Earnings

Guidance

Price Target

Analyst Ratings

Movers

ASND

BMRN

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 18 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $701,147, and 8 were calls, valued at $291,676.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $150.0 for Novo Nordisk over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $70.0 to $150.0 in the last 30 days. 
<h3>Novo Nordisk 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738949430_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.6</td>
<td>$0.51</td>
<td>$0.51</td>
<td>$79.00</td>
<td>$207.4K</td>
<td>55</td>
<td>5.2K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.68</td>
<td>$2.39</td>
<td>$2.44</td>
<td>$70.00</td>
<td>$146.4K</td>
<td>2.8K</td>
<td>1</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.76</td>
<td>$2.57</td>
<td>$2.76</td>
<td>$70.00</td>
<td>$110.4K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.65</td>
<td>$88.00</td>
<td>$54.3K</td>
<td>215</td>
<td>171</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$89.00</td>
<td>$50.5K</td>
<td>67</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>With a trading volume of 4,896,136, the price of NVO is up by 1.72%, reaching $88.67.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About Novo Nordisk

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A with and without inhibitors.
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915260" rel="noreferrer noopener">trial</a> initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investigational Mim8 before giving participants the option to change to once-monthly dosing after 26 weeks.
In part one of the FRONTIER3 study, participants received once-weekly doses of Mim8 for 26 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026</a>
In part two, participants could continue with once-weekly dosing or move to once-monthly dosing for the remaining 26 weeks.
<ul>
<li>The interim analysis reports results after part one of the study, with some preliminary data shared from part two, which continued following this analysis.</li>
<li>For part one of the study in children on once-weekly prophylaxis, the estimated mean (average) annualized bleeding rate (ABR) for treated bleeds was 0.53.</li>
</ul>
The median ABR was zero; 74.3% of participants had zero treated bleeds.
All children with hemophilia A with inhibitors (n=14) reported zero treated bleeds. After completing the initial 26 weeks of the study, 45% of participants moved to once-monthly Mim8, and the rest (55%) remained on the once-weekly dose.
The data showed that Mim8 was well-tolerated and efficacious.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In May 2024, Novo Nordisk released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in hemophilia A patients 12 years or older <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38797768/novo-nordisks-hemophilia-candidate-can-prevent-bleeding-episodes-effectively-regardless-of-dosing" rel="noreferrer noopener">with or without inhibitors</a>.
The trial achieved its co-primary endpoints by demonstrating a statistically significant and superior reduction of treated bleeding episodes with both once-weekly and once-monthly Mim8 versus no prophylaxis treatment and prior coagulation factor prophylaxis treatment.
In June 2024,&nbsp;Novo Nordisk acquired the Hemophilia A program and rights to 2seventy Bio Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39532373/novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma" rel="noreferrer noopener">cells for autoimmune disease</a>.
Price Action: NVO stock is down 2.33% at $89.20 during the premarket session on last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43542288/block-poised-for-growth-in-2025-analyst-predicts-outperformance-and-possible-sp-500-spot" target="_blank" rel="noreferrer noopener">Block In The S&amp;P500? BofA Analyst Says Company Meets All Criteria</a></li>
</ul>
Photo via Shutterstock

TSVT

Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026.
 &nbsp;

Novo Nordisk Announced Interim Results From Phase 3 FRONTIER3 Trial Of Mim8 In Children With Hemophilia A With And Without Inhibitors, Showed That 74.3% Of Children On Once-weekly Mim8 Prophylaxis Experienced Zero Treated Bleeds

Billionaire entrepreneur Mark Cuban on Thursday raised questions about Elon Musk&#8216;s intentions and his control over free speech, stirring a debate on the tech mogul&#8217;s influence on the government.
What Happened: On Thursday, Cuban, the minority owner of the Dallas Mavericks, took to X to express his concerns about Musk&#8217;s motivations and his control over free speech. 
He tweeted, &#8220;Anyone consider that maybe Elon's mission, is for Elon to get what he wants, rather than the country to get what you voted for?&#8221; 
He added, &#8220;The censorship of the platform you adore is in the hands of a single person, who is on a mission to make himself the most powerful person in the world. above and beyond the President of the United States.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Anyone consider that maybe Elon's mission, is for Elon to get what he wants, rather than the country to get what you voted for ? It's not a shock for Elon , or anyone, to put their personal goals first Elon seems to be on a mission to protect brand Elon at all costs. No ?…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1887526743541494092?ref_src=twsrc%5Etfw">February 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban&#8217;s remarks follow Musk&#8217;s increasing influence under President Donald Trump and the sweeping changes he is driving through the DOGE, which has<a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43460243/market-skeptical-of-doge-hype-questions-elon-musks-execution-bernstein-says"> faced skepticism from some critics.</a>
SEE ALSO: <a href="https://www.benzinga.com/news/legal/25/02/43539572/musk-allies-face-treasury-data-limits-as-judge-steps-in">Musk Allies Face Treasury Data Limits As Judge Steps In</a>
Why It Matters: Cuban&#8217;s comments add to the growing debate around Musk&#8217;s influence and his role in shaping policies. Reid Hoffman, the co-founder of LinkedIn Corporation and former COO of PayPal Holdings, has <a href="https://www.benzinga.com/politics/25/02/43548753/reid-hoffman-rebuffs-elon-musks-doge-theres-a-reason-the-government-doesnt-work-like-companies">previously criticized Musk&#8217;s decision-making</a>, suggesting that his &#8216;move fast and break things&#8217; approach should be more compassionate and judicious in the government context.
Furthermore, Musk&#8217;s Department of Government Efficiency, (DOGE), has <a href="https://www.benzinga.com/general/health-care/25/02/43520715/novo-nordisk-opposes-government-price-setting-as-elon-musks-doge-gains-access-to-cms-amid-bernie-sanders-criticism">recently gained access to the</a> Centers for Medicare and Medicaid Services (CMS), which has raised concerns about potential challenges for pharmaceutical companies. Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), a Danish pharmaceutical giant, is among those that could be affected by this move.
However, Alex Karp, The CEO of Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) <a href="https://www.benzinga.com/25/02/43487682/palantir-ceo-hails-elon-musks-doge-initiative-anticipates-positive-outcome">considers DOGE as &#8220;a revolution</a>&#8221; and a positive disruptor. &#8220;There will be ups and downs. There&#8217;s a revolution. Some people are going to get their heads cut off. We&#8217;re expecting to see really unexpected things and to win,&#8221; stated Karp.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43552235/tesla-hikes-model-x-price-by-5000-making-it-more-expensive-than-cybertruck">Tesla Hikes Model X Price By $5000, Making It More Expensive Than Cybertruck</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Tech

PLTR

PYPL

Mark Cuban Calls Out Elon Musk's Growing Influence Under Trump: 'On A Mission To Make Himself...Above And Beyond The President Of The United States'

Donald Trump's renewed push to <a href="https://www.benzinga.com/markets/emerging-markets/25/01/43133508/trump-wants-to-buy-greenland-for-us-security">take control of Greenland</a> is setting off a high-stakes showdown with Denmark, a small country with surprisingly big economic power. While Denmark might not have a military capable of standing up to the U.S., it has something just as powerful—control over key products that millions of Americans rely on every day.
<h2 class="wp-block-heading">Trump's Greenland Obsession and Trade War Threats</h2>
Trump has long wanted to bring Greenland under U.S. control, arguing it's <a href="https://www.benzinga.com/startups/25/01/43074027/why-trump-sees-greenland-as-a-2-billion-security-deal">vital for national security</a>.&nbsp;
"I'm talking about protecting the free world. You look at; you don't even need binoculars; you look outside," he said last month. "You have China ships all over the place. You have Russian ships all over the place. We're not letting that happen."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Vice President JD Vance recently said that Trump &#8220;doesn&#8217;t care what Europeans scream at us&#8221; and refused to rule out the use of military force.&nbsp;
Trump's latest strategy? Tariffs. He recently threatened to impose a 25% duty on all imports from Mexico and most from Canada, along with a 10% tariff on Chinese goods. He hinted that Denmark could be next if it refuses to give up Greenland.
Denmark's response? A firm &#8220;No&#8221; backed by European allies. Greenland's prime minister made it clear: "Greenland belongs to the people of Greenland." But Denmark isn't just pushing back with words. It has economic weapons that could cause immediate pain for U.S. consumers.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a>
<h2 class="wp-block-heading">Denmark's Secret Weapons: Ozempic, Wegovy, and Shipping</h2>
Denmark may be small, but it holds the keys to critical industries that Americans depend on, especially pharmaceuticals and global shipping.
<h3 class="wp-block-heading">1. Novo Nordisk Could Cut Off Ozempic and Wegovy</h3>
Denmark is home to Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the company behind <a href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows">Ozempic and Wegovy</a>, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs skyrocketing, Novo Nordisk has been expanding production in the U.S. But the active ingredient, semaglutide, is made in Denmark. If Denmark ordered Novo Nordisk to stop supplying the U.S., the supply of the drugs in the U.S. would disappear overnight.
Millions of Americans rely on Ozempic and Wegovy, and demand is so high that the U.S. has already faced shortages. On the other hand, Novo Nordisk would likely have no issues finding plenty of customers in other markets.&nbsp;
Trending: According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a>
<h3 class="wp-block-heading">2. Maersk Could Halt U.S. Shipping</h3>
Denmark is also home to Maersk, the world's second-largest container shipping company, which transports 14.3% of the global container fleet. If Maersk were to stop shipping goods to and from the U.S., it would cause immediate chaos in supply chains.
Major U.S. ports like Los Angeles, Houston, and New York rely on Maersk for everything from electronics to clothing. Since global shipping is already near full capacity, there wouldn't be enough ships available to pick up the slack. This would drive up shipping costs and lead to shortages of everyday products in the U.S.
Beyond that, Denmark is also a major supplier of <a href="https://www.benzinga.com/news/24/04/38045479/lego-billionaires-wealth-surges-as-investment-portfolio-turns-profitable">Lego toys</a>, hearing aids, insulin, medical instruments, and pork. Tariffs or trade restrictions could send prices skyrocketing on all of these products, hurting American consumers more than Denmark.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">Trump's Tariff Pause on Mexico and Canada Adds More Uncertainty</h2>
Just days ago, Trump announced a <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">one-month pause</a> on tariffs against Mexico and Canada after last-minute talks. Mexico agreed to deploy 10,000 troops to its border to curb fentanyl trafficking and illegal migration, while Canada committed to tightening border security and implementing a $1.3 billion border plan.
But this pause doesn't mean tariffs are off the table. Trump is still threatening more trade wars, and Denmark and the whole EU are the next target. If Trump imposes tariffs on European exports, it would raise prices on EU goods coming into the U.S., making products like pharmaceuticals, medical devices, and food products significantly more expensive for American consumers.
See Also: Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a>
<h2 class="wp-block-heading">Denmark&#8217;s Economic Might is No Joke</h2>
Denmark may be a small country, but it has massive leverage over the U.S. economy. If Trump pushes too hard on Greenland, Denmark could strike back in ways that everyday Americans would feel immediately. From sky-high drug prices to shipping disruptions, Trump's threats of tariffs could backfire in a big way.
For now, <a href="https://www.benzinga.com/24/12/42679581/trump-effect-denmark-boosts-greenlands-defense-budget-amid-president-elects-renewed-acquisition-interest">Denmark is standing firm</a>, and <a href="https://www.benzinga.com/startups/25/01/43083783/we-dont-want-to-be-americans-greenlanders-speak-out-on-trumps-plan">Greenland isn't for sale</a>. The question is: Will Trump push Denmark too far and spark an economic war he wasn't expecting?
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Image from ShutterStock

Denmark Could Ban Or Push Ozempic, Wegovy And Shipping Prices Through The Roof If Trump Escalates Over Greenland

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced that its weight-loss drug Wegovy has reached 1.2 million U.S. patients. Of these, 55 million individuals are covered by insurance, and over 80% pay less than $25 per prescription, according to statements made during the company&#8217;s <a href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" target="_blank" rel="noopener">fourth-quarter 2024 earnings call</a>.
What Happened: The Danish pharmaceutical giant faces potential challenges as semaglutide-containing products, including Wegovy, Ozempic, and Rybelsus, have been selected for the second round of Centers for Medicare and Medicaid Services (CMS) price negotiations. 
The negotiations are set to conclude in early November, with maximum fair prices to be published by month-end and implementation scheduled for Jan.1, 2027.
&#8220;We oppose government price setting like we have from the beginning,&#8221; stated David Moore, Executive Vice President of U.S. Operations and Global Business Development at Novo Nordisk. 
The pricing debate has drawn attention from diverse quarters, including Tesla Inc. CEO Elon Musk and Sen.&nbsp;Bernie Sanders, (I-VT), who have both criticized the <a href="https://www.benzinga.com/personal-finance/24/09/41082125/stop-ripping-us-off-incredibly-elon-musk-and-bernie-sanders-seem-to-agree-on-this-one-thing-i-re">drug&#8217;s high U.S. costs</a>. 
Sanders highlighted that Wegovy&#8217;s monthly prescription costs $1,349 in the U.S., compared to significantly lower prices in other countries: $186 in Denmark, $140 in Germany, and $92 in the U.K.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43518087/official-trump-coin-jumps-427-but-still-75-below-januarys-all-time-high">TRUMP Meme Coin Jumps 4.27%, Outpaces Bitcoin, Ethereum, And Dogecoin, But It&#8217;s Still Nowhere Near January Highs</a>
Why It Matters: The situation has become more complex with the involvement of Musk&#8217;s Department of Government Efficiency (DOGE), which has gained access to CMS systems. The move is part of a broader initiative to identify potential fraud and waste in government healthcare spending, though CMS maintains that two senior agency veterans are overseeing the collaboration to ensure appropriate system access.
Despite these challenges, Novo Nordisk remains focused on market expansion. &#8220;Building a sustainable obesity market for the long term is through market access and having patients have a reasonable co-pay,&#8221; Moore said. 
Looking ahead, Novo Nordisk <a href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026">projects sales growth</a> between 16% and 24% in constant exchange rates for 2025, though this represents a decrease from the 26% growth achieved in 2024. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43519568/ubers-strong-q4-offset-by-11-billion-forex-headwind-currency-devaluation-thanks-to-tariff-wars-drives-weak-q1-outlook">Uber&#8217;s Strong Q4 Offset By $1.1 Billion Forex Headwind, Currency Devaluation: Ongoing Tariff Wars Drive Weak Q1 Outlook</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Novo Nordisk Opposes 'Government Price Setting' As Elon Musk's DOGE Gains Access To CMS Amid Bernie Sanders' Criticism

Press Releases

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVO

NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – NV

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO

Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO

Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

米国株は反発し、結果はまちまちに
ダウ平均は0.8％近く下落し、39,112.16ドルでした。一方、S&amp;P 500は0.4％以上上昇し、5,469.30ドルでレギュラーセッションを終えました。ナスダック指数はほぼ1.3％上昇し、17,717.65ドルで取引を終了しました。
これらは、小売トレーダーや投資家の関心を集めたトップ銘柄です。
Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)
報道によると、フォルクスワーゲンがRivianに対して電気自動車事業の一環として50億ドルを投資する計画を立てていることが明らかになり、Rivianの株価は8.63％急騰して11.96ドルで取引を終えました。ドイツ自動車大手は、<a href="https://www.benzinga.com/news/24/06/39490832/rivian-stock-is-rallying-after-the-close-whats-going-on">1,000億ドルを即時投資し</a>、今後の追加投資で4,000億ドルを投入すると発表しました。この合弁会社では、次世代型のバッテリー駆動車両の開発に焦点を当てています。
Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)
火曜日、Lucid Groupの株価は2.34％下落し、2.50ドルで取引終了しました。同社は、グローバルコミュニケーション担当幹部にNick Twork氏を任命したことを発表し、Twork氏はLucidのグローバルコミュニケーションチームを監督し、同社CEOPeter Rawlinson氏に<a href="https://www.benzinga.com/news/24/06/39491785/whats-going-on-with-lucid-stock-tuesday">直接報告を行います</a>。
関連記事: <a href="https://www.benzinga.com/news/earnings/24/06/39453063/nasdaq-futures-slip-as-nvidia-sell-off-continues-s-p-500-futures-hold-up-analyst-says-valuations-wi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">ナスダック先物が下落、Nvidiaの売却が継続、S&amp;P 500先物は保持 ～ アナリストは「評価は続く」と述べる</a>
Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
株価が1.52％上昇し、141.12ドルで取引を終えました。RosenblattのアナリストであるHans Mosesmann氏は、当社が歴史上最も重要なメモリサイクルの1つに突入したことを受け、<a href="https://www.benzinga.com/news/24/06/39487802/what-to-expect-from-micron-techs-q3-earnings-bullish-analyst-lays-out-forecast">Micronの株式評価を引き続きBuyとし、225ドルの目標株価を設定しました。</a>
Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)
火曜日は、Novo Nordiskの株価が3.25％上昇し、146.91ドルで取引を終えました。この上昇は、中国がNovoの減量薬「Wegovy」の承認を発表したことによるものです。中国は世界で2番目に人口が多い国であり、世界で最も多くの肥満人口が存在すると見られています。<a href="https://www.benzinga.com/news/24/06/39484486/why-novo-nordisk-shares-are-trading-higher-tuesday">続きを読む</a>。
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
火曜日、Teslaの株価は2.61％上昇し、187.35ドルで取引を終えました。Emil Michael氏は、前任のウーバー・テクノロジーズ社最高ビジネス担当幹部であったが、ロボタクシーの財務的実現可能性について<a href="https://www.benzinga.com/news/24/06/39471827/can-tesla-robotaxi-google-waymo-replace-lyft-and-uber-former-exec-says-these-things-are-expensive">最近疑問を表明しています</a>、それを製造するのに高いコストがかかると指摘してい ます。
ShutterstockのWHYFRAMEによる写真

「ノーボ・ノルディスク (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) は、同社の減量薬の需要増加に対応するため、米国での製造拠点の拡大に41億ドルを投資する予定だ。
出来事：ノルウェーの製薬会社は、同社が発表したリリースの中で、北カロライナ州のローリー近くに新しい140万平方フィートの製造工場を建設する予定で、これにより同社製造拠点の規模が倍増するという。 この追加生産能力は、2027年から2029年の間に運用される予定だ。
この投資は、新しいタイプの糖尿病および減量薬であるGLP-1の市場の拡大に対応したものだ。金融タイムズの報告によると、この市場は2030年までに1,300億ドルに達すると予想されている。同社の投資は、同社の減量薬Wegovyと糖尿病治療薬であるOzempicの最近の製造不足にも対応し、Eli Lillyの競合薬であるZepboundとMounjaroにも利益をもたらすだろう。
関連ニュース： <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448955/dogecoin-killer-shiba-inu-falters-here-is-what-these-key-indicators-reveal-about-its-short?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">ドージコインのライバルが躓く：短期的な見通しを示す重要な指標</a>
この投資は、製薬業界全体のトレンドの一部にすぎない。2023年には、ノルヴェーの製薬会社は、自社のデンマークの製造施設を拡張するために<a href="https://www.benzinga.com/general/biotech/23/11/35722046/novo-nordisk-seeks-obesity-diabetes-bolt-on-deals-as-it-beefs-up-capacity-to-meet-soaring-demand">60億ドルの投資を発表</a>している。
なぜ重要なのか：減量薬の需要の急増は、ノルボ・ノルディスクの業績に大きな影響を与えている。供給が追いつかないという課題や、Eli Lillyからの競合にもかかわらず、同社は米国の患者数がWegovy（減量薬）の服用を開始したという報告を見ている。 このことにより、同社の減量薬の売上げは9,380億クローネ（約135億ドル）に増加し、2024年第1四半期に2倍になった。
しかし、ノルボ・ノルディスクの施設の供給上の課題はEli Lillyにとって有利に働くだろう。米国企業に関しては、<a href="https://www.benzinga.com/general/biotech/24/06/39463758/will-novo-nordisk-building-fires-serve-as-a-catalyst-for-eli-lilly-redditors-see-a-stock-split-fo">潜在的な株式分割について憶測が広まっている</a>。Eli Lillyの減量薬Zepboundは、特に大都市圏で過去に発生した供給上の課題が解決され、ノルボ・ノルディスクの供給制限から利益を得る可能性がある。
銘柄の値動き：月曜日、ノルボ・ノルディスクA/Sの株価は1株142.28ドルで取引を終了し、その日の上昇率は0.23％でした。アフターマーケット取引では、0.28%上昇しました。ノルボ・ノルディスクの株は、ヤーレ初めて日付から見て、Benzinga Proのデータによると、これまで39.34％増加しています。 。
次の一手： <a href="https://www.benzinga.com/news/earnings/24/06/39453063/nasdaq-futures-slip-as-nvidia-sell-off-continues-s-p-500-futures-hold-up-analyst-says-valuations-wi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nasdaq先物はノビディアの売りが続く中で下落、S＆P500先物は持ちこたえ：アナリストは「バリュエーションは爆発的に向上し、売却の絶好の機会になる」と述べた</a>

Comments

Novo Nordisk

ニュース

最新ニュース Novo Nordisk (NYSE:NVO) 株価情報

水曜日, 6 26, 2024

火曜日, 6 25, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル